In this chapter, we have focused on PI3Kδ signaling in normal B cellsand the relevance of this to the treatment of CLL with the recently approved drugidelalisib—the first PI3K inhibitor to be approved for clinical use. The gene discussed is PIK3CD; the disease is B-cell chronic lymphocytic leukemia.